Soligenix (SNGX) EPS (Basic) Growth (5y) (2016 - 2026)
Soligenix (SNGX) EPS (Basic) Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - |
| 10 | Soligenix | 6.34 Mn | 6.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.45% |
| Mar 31, 2026 | 55.20% |
| Dec 31, 2025 | 59.03% |
| Sep 30, 2025 | 47.41% |
| Jun 30, 2025 | 49.37% |
| Mar 31, 2025 | 58.41% |
| Dec 31, 2024 | 44.94% |
| Sep 30, 2024 | 52.57% |
| Jun 30, 2024 | 45.69% |
| Mar 31, 2024 | 33.12% |
| Dec 31, 2023 | 41.87% |
| Sep 30, 2023 | 36.86% |
| Jun 30, 2023 | 39.17% |
| Mar 31, 2023 | 38.51% |
| Dec 31, 2022 | 56.49% |
| Sep 30, 2022 | 18.14% |
| Jun 30, 2022 | 33.62% |
| Mar 31, 2022 | 21.27% |
| Dec 31, 2021 | 60.71% |
| Sep 30, 2021 | 28.30% |